Expression of HMGB2 indicates worse survival of patients and is required for the maintenance of Warburg effect in pancreatic cancer

Acta Biochimica et Biophysica Sinica

Volumn 49, Issue 2, 2017, Pages 119-127

  Cai, Xin ^a   Ding, Hongjian ^b   Liu, Yanxia ^b   Pan, Gaofeng ^b   Li, Qingguo ^b,c   Yang, Zhen ^b   Liu, Weiyan ^b  

^a Shanghai Proton and Heavy Ion Center   (China)

^b FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

HMGB2; pancreatic cancer; Warburg effect

Indexed keywords

GLUCOSE TRANSPORTER 1; HEXOKINASE; HEXOKINASE 2, HUMAN; HIGH MOBILITY GROUP B2 PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ISOENZYME; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE 5; MTOR PROTEIN, HUMAN; PROTEIN KINASE B; SLC2A1 PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; GLYCOLYSIS; HEK293 CELL LINE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE TRANSPORTER TYPE 1; GLYCOLYSIS; HEK293 CELLS; HEXOKINASE; HMGB2 PROTEIN; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; ISOENZYMES; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TOR SERINE-THREONINE KINASES;

EID: 85016187341     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmw124     Document Type: Article

References (35)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015, 65: 5-29.
2. Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet 2016, 10039: 73-85.
3. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet 2011, 378: 607-620.
4. Penzo M, Molteni R, Suda T, Samaniego S, Raucci A, Habiel DM, Miller F, et al. Inhibitor of NF-kappa B kinases alpha and beta are both essential for high mobility group box 1-mediated chemotaxis [corrected]. J Immunol 2010, 184: 4497-4509.
5. Hidalgo M, Von Hoff DD. Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas. Clin Cancer Res 2012, 18: 4249-4256.
6. Ying H, Dey P, Yao W, Kimmelman AC, Draetta GF, Maitra A, DePinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2016, 30: 355-385.
7. Cantor JR, Sabatini DM. Cancer cell metabolism: one hallmark, many faces. Cancer Discov 2012, 2: 881-898.
8. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144: 646-674.
9. Warburg O. On the origin of cancer cells. Science 1956, 123: 309-314.
10. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324: 1029-1033.
11. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 2012, 21: 297-308.
12. Gordan JD, Thompson CB, Simon MC. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 2007, 12: 108-113.
13. Li B, Simon MC. Molecular pathways: targeting MYC-induced metabolic reprogramming and oncogenic stress in cancer. Clin Cancer Res 2013, 19: 5835-5841.
14. Lu C, Thompson CB. Metabolic regulation of epigenetics. Cell Metab 2012, 16: 9-17.
15. Bianchi ME, Beltrame M. Upwardly mobile proteins. Workshop: the role of HMG proteins in chromatin structure, gene expression and neoplasia. EMBO Rep 2000, 1: 109-114.
16. Bianchi ME, Agresti A. HMG proteins: dynamic players in gene regulation and differentiation. Curr Opin Genet Dev 2005, 15: 496-506.
17. Ishiguro H, Nakaigawa N, Miyoshi Y, Fujinami K, Kubota Y, Uemura H. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate 2005, 64: 92-100.
18. Yang GL, Zhang LH, Bo JJ, Huo XJ, Chen HG, Cao M, Liu DM, et al. Increased expression of HMGB1 is associated with poor prognosis in human bladder cancer. J Surg Oncol 2012, 106: 57-61.
19. Jiang W, Wang Z, Li X, Fan X, Duan Y. High-mobility group box 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Pathol Oncol Res 2012, 18: 293-298.
20. Akaike H, Kono K, Sugai H, Takahashi A, Mimura K, Kawaguchi Y, Fujii H. Expression of high mobility group box chromosomal protein-1 (HMGB-1) in gastric cancer. Anticancer Res 2007, 27: 449-457.
21. Liu PL, Tsai JR, Hwang JJ, Chou SH, Cheng YJ, Lin FY, Chen YL, et al. High-mobility group box 1-mediated matrix metalloproteinase-9 expression in non-small cell lung cancer contributes to tumor cell invasiveness. Am J Respir Cell Mol Biol 2010, 43: 530-538.
22. Guo ZS, Liu Z, Bartlett DL, Tang D, Lotze MT. Life after death: targeting high mobility group box 1 in emergent cancer therapies. Am J Cancer Res 2013, 3: 1-20.
23. Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G, Piqani B, et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006, 124: 1283-1298.
24. Ji S, Qin Y, Shi S, Liu X, Hu H, Zhou H, Gao J, et al. ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer. Cell Res 2015, 25: 561-573.
25. Huqun, Ishikawa R, Zhang J, Miyazawa H, Goto Y, Shimizu Y, Hagiwara K, et al. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer. Cancer 2012, 118: 1599-1606.
26. Pathiraja TN, Thakkar KN, Jiang S, Stratton S, Liu Z, Gagea M, Shi X, et al. TRIM24 links glucose metabolism with transformation of human mammary epithelial cells. Oncogene 2015, 34: 2836-2845.
27. Campbell PA, Rudnicki MA. Oct4 interaction with Hmgb2 regulates Akt signaling and pluripotency. Stem Cells 2013, 31: 1107-1120.
28. Thomas JO. HMG1 and 2: architectural DNA-binding proteins. Biochem Soc Trans 2001, 29: 395-401.
29. Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 2013, 4: e532.
30. El Mjiyad N, Caro-Maldonado A, Ramirez-Peinado S, Munoz-Pinedo C. Sugar-free approaches to cancer cell killing. Oncogene 2011, 30: 253-264.
31. Jeong SM, Xiao C, Finley LW, Lahusen T, Souza AL, Pierce K, Li YH, et al. SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. Cancer Cell 2013, 23: 450-463.
32. Cao X, Fang L, Gibbs S, Huang Y, Dai Z, Wen P, Zheng X, et al. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemother Pharmacol 2007, 59: 495-505.
33. Zhou M, Zhao Y, Ding Y, Liu H, Liu Z, Fodstad O, Riker AI, et al. Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol. Mol Cancer 2010, 9: 33.
34. Coloff JL, Macintyre AN, Nichols AG, Liu T, Gallo CA, Plas DR, Rathmell JC. Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition. Cancer Res 2011, 71: 5204-5213.
35. Zhao YH, Zhou M, Liu H, Ding Y, Khong HT, Yu D, Fodstad O, et al. Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth. Oncogene 2009, 28: 3689-3701.